Skip to main navigation Skip to search Skip to main content

Revised consensus statement on the preventive and symptomatic care of patients with leukodystrophies

  • Laura A. Adang
  • , Omar Sherbini
  • , Laura Ball
  • , Miriam Bloom
  • , Anil Darbari
  • , Hernan Amartino
  • , Donna DiVito
  • , Florian Eichler
  • , Maria Escolar
  • , Sarah H. Evans
  • , Ali Fatemi
  • , Jamie Fraser
  • , Leslie Hollowell
  • , Nicole Jaffe
  • , Christopher Joseph
  • , Mary Karpinski
  • , Stephanie Keller
  • , Ryan Maddock
  • , Edna Mancilla
  • , Bruce McClary
  • Jana Mertz, Kiley Morgart, Thomas Langan, Richard Leventer, Sumit Parikh, Amy Pizzino, Erin Prange, Deborah L. Renaud, William Rizzo, Jay Shapiro, Dean Suhr, Teryn Suhr, Davide Tonduti, Jacque Waggoner, Amy Waldman, Nicole I. Wolf, Ayelet Zerem, Joshua L. Bonkowsky, Genevieve Bernard, Keith van Haren, Adeline Vanderver*
*Corresponding author for this work
  • University of Pennsylvania
  • Children's National Medical Center
  • Hospital Universitario Austral
  • Harvard University
  • University of Pittsburgh
  • Kennedy Krieger Institute
  • Women and Children's Hospital of Buffalo
  • Emory University
  • Hunter James Kelly Research Institute
  • University of Melbourne
  • Cleveland Clinic Foundation
  • Mayo Clinic Rochester, MN
  • University of Nebraska Medical Center
  • MLD Foundation
  • IRCCS Fondazione Istituto Neurologico Carlo Besta - Milano
  • Hunter's Hope Foundation
  • Edith Wolfson Medical Center Israel
  • University of Utah
  • McGill University
  • Stanford University

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Leukodystrophies are a broad class of genetic disorders that result in disruption or destruction of central myelination. Although the mechanisms underlying these disorders are heterogeneous, there are many common symptoms that affect patients irrespective of the genetic diagnosis. The comfort and quality of life of these children is a primary goal that can complement efforts directed at curative therapies. Contained within this report is a systems-based approach to management of complications that result from leukodystrophies. We discuss the initial evaluation, identification of common medical issues, and management options to establish a comprehensive, standardized care approach. We will also address clinical topics relevant to select leukodystrophies, such as gallbladder pathology and adrenal insufficiency. The recommendations within this review rely on existing studies and consensus opinions and underscore the need for future research on evidence-based outcomes to better treat the manifestations of this unique set of genetic disorders.

Original languageEnglish
JournalMolecular genetics and metabolism
Volume122
Issue number1-2
DOIs
Publication statusPublished - Sept 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Care
  • Consensus
  • Leukodystrophy
  • Outcomes
  • Prevention
  • Therapy

Fingerprint

Dive into the research topics of 'Revised consensus statement on the preventive and symptomatic care of patients with leukodystrophies'. Together they form a unique fingerprint.

Cite this